Sichuan Hanyuan County People's Hospital, Hanyuan 625300, China.
Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Biosensors (Basel). 2022 Oct 13;12(10):870. doi: 10.3390/bios12100870.
While there are many clinical drugs for prophylaxis and treatment, the search for those with low or no risk of side effects for the control of infectious and non-infectious diseases is a dilemma that cannot be solved by today's traditional drug development strategies. The need for new drug development strategies is becoming increasingly important, and the development of new drugs from traditional medicines is the most promising strategy. Many valuable clinical drugs have been developed based on traditional medicine, including drugs with single active ingredients similar to modern drugs and those developed from improved formulations of traditional drugs. However, the problems of traditional isolation and purification and drug screening methods should be addressed for successful drug development from traditional medicine. Advances in microfluidics have not only contributed significantly to classical drug development but have also solved many of the thorny problems of new strategies for developing new drugs from traditional drugs. In this review, we provide an overview of advanced microfluidics and its applications in drug development (drug compound synthesis, drug screening, drug delivery, and drug carrier fabrication) with a focus on its applications in conventional medicine, including the separation and purification of target components in complex samples and screening of active ingredients of conventional drugs. We hope that our review gives better insight into the potential of traditional medicine and the critical role of microfluidics in the drug development process. In addition, the emergence of new ideas and applications will bring about further advances in the field of drug development.
虽然有许多临床药物可用于预防和治疗,但寻找那些副作用风险低或无的药物来控制感染和非传染性疾病,是当今传统药物开发策略无法解决的难题。因此,需要开发新的药物开发策略,而从传统药物中开发新药是最有前途的策略之一。许多有价值的临床药物都是基于传统药物开发的,包括与现代药物类似的单一活性成分药物和从传统药物改良制剂开发的药物。然而,从传统药物中成功开发药物需要解决传统的分离和纯化以及药物筛选方法的问题。微流控技术的进步不仅为经典药物开发做出了重大贡献,而且还解决了许多从传统药物开发新药的新策略的棘手问题。在本文中,我们概述了先进的微流控技术及其在药物开发(药物化合物合成、药物筛选、药物输送和药物载体制造)中的应用,重点介绍了其在常规药物中的应用,包括复杂样品中目标成分的分离和纯化以及常规药物的活性成分筛选。我们希望我们的综述能更好地了解传统医学的潜力以及微流控在药物开发过程中的关键作用。此外,新思想和应用的出现将推动药物开发领域的进一步发展。